StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NAGE$3.53-2.15%
Fair $3.53+0.0%

NAGE

Niagen Bioscience, Inc.

Healthcare / BiotechnologyNasdaqCM

$3.53

-0.08 (-2.15%)

Fairly Valued+0.0%Fair Value $3.53Fund rank 30/100 · Data gapFallback financials|
SA 53/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 31% · confianza 25%

FCF escenarios

weak_data · normalized FCF $11.9M · quality 52.0/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 32/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

53/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 14Warnings: 0unknown: 14
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists.
Thesis & Journal · NAGELocal privado en este navegador · Niagen Bioscience, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$281M

P/E

16.8x

↓

EV/EBITDA

15.2x

↑

ROE

22.7%

↑

Gross Margin

64.3%

↑

Debt/Equity

0.04

↓
52-Week Range$4
$4$15

TradingView lightweight chart

NAGE price, volumen y niveles de valoración

Último $3.533Periodo -69.8%
Fair value: $3.533

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2011–2025 · 14 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

10.2%

FCF / Net income

0.76x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $129.4M · net income $17.4M · FCF $13.2M

2011-FY → 2025-FY

Gross margin

64.3%— pts

Operating margin

11.0%— pts

Net margin

13.4%— pts

FCF margin

10.2%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2013
2012
2011
Income Statement
Revenue$129.4M$129.4M$99.6M$83.6M$72.0M$67.4M$59.3M$46.3M$31.6M$21.2M—————
Net Income$17.4M$17.4M$8.6M$-4.9M$-16.5M$-27.1M$-19.9M$-32.1M$-33.3M$-11.4M$-2.9M$-5.4M$-4.4M$-11.7M$-7.9M
EBITDA$15.7M$15.7M$9.2M$-3.9M$-16.7M———$-32.6M$-15.9M$-2.6M$-5.0M$-4.1M——
EPS0.200.200.11-0.07-0.24-0.40-0.33———————-0.36
Gross Margin64.3%64.3%61.8%60.8%59.4%61.5%59.5%55.7%50.9%49.4%—————
Operating Margin11.0%11.0%7.8%-6.7%-25.9%-40.1%-33.5%-67.6%-105.1%-77.2%—————
Net Margin13.4%13.4%8.6%-5.9%-23.0%-40.2%-33.6%-69.4%-105.6%-53.7%—————
Balance Sheet
Debt/Equity0.040.040.060.120.15—————0.000.49———
Current Ratio4.614.61—————————————
Cash Flow
Free Cash Flow$13.2M$13.2M$11.9M$7.0M$-15.4M——$-21.2M$-22.2M$-11.0M$-4.4M$-2.7M$-4.0M$-10.1M$-4.2M
Returns
ROE22.7%22.7%18.5%-17.4%-57.7%-85.5%-121.3%-157.2%-122.6%-21.1%-29.4%-134.8%-78.0%-292.0%-308.2%
Valuation
P/E16.8216.8250.09————————————
EV/EBITDA15.2415.2442.19————————————
P/B3.943.949.343.854.67——————————
Growth & Yield
Revenue Growth29.9%29.9%19.2%16.0%—13.8%28.0%46.7%48.8%——————
EPS Growth81.8%81.8%257.1%70.8%—-21.2%—————————

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

16.2%

exigente

EPS terminal req.

$0.31

Spread vs growth

65.7%

5Y implied EPS CAGR

13.7%

razonable

EPS terminal req.

$0.38

Spread vs growth

68.2%

10Y implied EPS CAGR

11.8%

razonable

EPS terminal req.

$0.61

Spread vs growth

70.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -69.9%

Total return

-69.9%

Start / end P/E

106.6x → 17.7x

EPS bridge

0.11 → 0.20

Residual

-68.3%

EPS growth+81.8%
Multiple rerating-83.4%
Dividend+0.0%
Residual / FX / buybacks / cross-term-68.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.